11 results
8-K
EX-99.1
GLTO
Galecto Inc
27 Jan 22
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
8:31am
injury, cytokine storm, T-cell exhaustion and organ micro-thrombosis, and the results from this trial suggest that GB0139 has the potential … for treatment of viral induced acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
The study met its primary endpoint of safety as there were
10-K
2020 FY
GLTO
Galecto Inc
29 Mar 21
Annual report
6:03am
processes that drive fibrosis and certain types of cancers.
Fibrosis is the development of abnormal fibrous connective tissue in response to injury … injury driven by a different stimulus or the autoimmune processes. The process of chronic inflammation leads to a progressive accumulation
10-Q
2020 Q3
GLTO
Galecto Inc
11 Dec 20
Quarterly report
7:30am
to cause injury or are found to be otherwise unsuitable during clinical trials, manufacturing, marketing or sale. Any such product liability claims may … result in:
inability to bring a product candidate to the market;
decreased demand for our products;
injury to our reputation;
withdrawal of clinical
S-1/A
bwz3bw l7
22 Oct 20
IPO registration (amended)
6:13am
S-1
wwo37v50b7pwa3fq9v
7 Oct 20
IPO registration
5:01pm
424B4
owzxtt fut
30 Oct 20
Prospectus supplement with pricing info
4:31pm
DRS
llx4u4vzbmeg2zj0lho
2 Sep 20
Draft registration statement
12:00am
S-1/A
EX-10.1
wjemxybop 2dyhtvmune
22 Oct 20
IPO registration (amended)
6:13am
- Prev
- 1
- Next